PDCD1 and melanoma: ,4 Antibodies blocking PD-L1 or PD-1 inhibit this immunosuppressive pathway and have led to improvements in patient survival in melanoma,5,6 lung cancer,7,8 bladder cancer,9,10 and Merkel cell carcinoma,11,12 among others.2